Time will tell: community acceptability of HIV vaccine research before and after the “Step Study” vaccine discontinuation

• Type of Material: Article
• Authors: Paula M Frew, Emory University; Mark Mulligan, Emory University; Su-I Hou, University of Georgia; Kayshin Chan, The Hope Clinic of the Emory Vaccine Center; Carlos Del Rio, Emory University
• Language: English
• Date: 2010-09-01
• Publisher: Dove Medical Press
• Publication Version: Final Published Version
• Copyright Statement: © 2010 Frew et al, publisher and licensee Dove Medical Press Ltd.
• License: Creative Commons Attribution-Noncommercial 3.0 Unported
• Final Published Version (URL): http://www.dovepress.com/time-will-tell-community-acceptability-of-hiv-vaccine-research-before--peer-reviewed-article-OAJCT
• Title of Journal or Parent Work: Open Access Journal of Clinical Trials
• ISSN: 1179-1519
• Volume: 2010
• Issue: 2
• Start Page: 149
• End Page: 156
• Grant/Funding Information: Partial support for this study was provided by the Emory Center for AIDS Research (P30 AI050409), the Emory Vaccine Center (U19 AI057266), the Emory HIV/AIDS Clinical Trials Unit (U01 AI069418), the Georgia Research Alliance, and Merck and Company (Protocol V520/023-00).
• Keywords: men-who-have-sex-with-men; willingness to participate; recruitment; AIDS; community engagement
• Research Categories: Psychology, Clinical; Biology, Virology

Abstract

Objective This study examines whether men-who-have-sex-with-men (MSM) and transgender (TG) persons’ attitudes, beliefs, and risk perceptions toward human immunodeficiency virus (HIV) vaccine research have been altered as a result of the negative findings from a phase 2B HIV vaccine study. Design We conducted a cross-sectional survey among MSM and TG persons (N = 176) recruited from community settings in Atlanta from 2007 to 2008. The first group was recruited during an active phase 2B HIV vaccine trial in which a candidate vaccine was being evaluated (the “Step Study”), and the second group was recruited after product futility was widely reported in the media. Methods Descriptive statistics, t tests, and chi-square tests were conducted to ascertain differences between the groups, and ordinal logistic regressions examined the influences of the above-mentioned factors on a critical outcome, future HIV vaccine study participation. The ordinal regression outcomes evaluated the influences on disinclination, neutrality, and inclination to study participation. Results Behavioral outcomes such as future recruitment, event attendance, study promotion, and community mobilization did not reveal any differences in participants’ intentions between the groups. However, we observed greater interest in HIV vaccine study screening (t = 1.07, P < 0.05) and enrollment (t = 1.15, P < 0.05) following negative vaccine findings. Means on perceptions, attitudes, and beliefs did not differ between the groups. Before this development, only beliefs exhibited a strong relationship on the enrollment intention (β = 2.166, P = 0.002). However, the effect disappeared following negative trial results, with the positive assessment of the study-site perceptions being the only significant contributing factor on enrollment intentions (β = 1.369, P = 0.011). Conclusion Findings show greater enrollment intention among this population in the wake of negative efficacy findings from the Step Study. The resolve of this community to find an HIV vaccine is evident. Moreover, any exposure to information disseminated in the public arena did not appear to negatively influence the potential for future participation in HIV vaccine studies among this population. The results suggest that subsequent studies testing candidate vaccines could be conducted in this population.